<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>23726310</identifier>
<setSpec>1989-7286</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Flores-Moreno, I</dc:author>
<dc:author>Moreno-Valladares, A</dc:author>
<dc:author>Bautista Ruescas, V</dc:author>
<dc:author>Cava-Valenciano, C</dc:author>
<dc:author>Copete-Piqueras, S</dc:author>
<dc:description xml:lang="en">CASE REPORT The case is presented of a 32-year-old man referring to metamorphopsia and blurred vision in both eyes for 3 days. Best corrected visual acuity of 20/32 in the right eye and 20/25 in the left eye. Fundus examination revealed the presence of drusen-like deposits, suggestive of Sorsby's fundus dystrophy (SFD) and choroidal neovascularization (CNV) bilaterally. The patient received intravitreal ranibizumab. Visual acuity improved to 20/20 in both eyes at 6-months follow-up, and results of fundus examination showed complete regression of neovascularization. No mutations were found in the TIMP-3 gene. DISCUSSION The known mutations in TIMP-3 may not be extended to all patients with SFD. The use of intravitreal ranibizumab may be considered as a therapeutic option in CNV secondary to SFD.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2013 Jun </dc:date>
<dc:title xml:lang="es">Tratamiento antiangiogénico en fondo de distrofia de Sorsby sin mutación en gen de TIMP-3.</dc:title>
<dc:title xml:lang="en">[Antiangiogenic therapy in Sorsby's fundus dystrophy without a mutation in the TIMP-3 gene].</dc:title>
<dc:publisher>Archivos de la Sociedad Espanola de Oftalmologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
